脂质体两性霉素B与利什曼病：剂量与反应
Liposomal amphotericin B and leishmaniasis: dose and response.
作者信息
Sundar Shyam, Chakravarty Jaya
机构信息
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India.
出版信息
J Glob Infect Dis. 2010 May;2(2):159-66. doi: 10.4103/0974-777X.62886.
Abstract
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
摘要
脂质体两性霉素B已越来越频繁地用于治疗内脏利什曼病（VL）。它是地中海地区免疫功能正常患者的首选治疗药物，也是HIV/VL合并感染的首选药物。尽管寄生虫的易感性存在区域差异，但20mg/kg的总剂量对免疫功能正常的患者有效。迫切需要对脂质体两性霉素B治疗HIV-VL合并感染患者及二级预防进行随机临床试验，以优化该亚组的治疗。随着脂质体两性霉素B在流行地区以优惠价格供应，短程联合治疗可能成为一种可行的替代方案。
相似文献
1
Liposomal amphotericin B and leishmaniasis: dose and response.
J Glob Infect Dis. 2010 May;2(2):159-66. doi: 10.4103/0974-777X.62886.
2
Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Clin Infect Dis. 2006 Oct 1;43(7):917-24. doi: 10.1086/507530. Epub 2006 Aug 28.
3
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Clin Infect Dis. 2009 Jan 15;48(2):e16-22. doi: 10.1086/595710.
4
Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Clin Infect Dis. 2011 Oct;53(7):e91-8. doi: 10.1093/cid/cir521.
5
Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Trop Med Int Health. 2014 Feb;19(2):146-52. doi: 10.1111/tmi.12238. Epub 2014 Jan 17.
6
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
BMC Infect Dis. 2016 Oct 10;16(1):548. doi: 10.1186/s12879-016-1746-1.
7
Current and emerging medications for the treatment of leishmaniasis.
Expert Opin Pharmacother. 2019 Jul;20(10):1251-1265. doi: 10.1080/14656566.2019.1609940. Epub 2019 May 7.
8
Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.
Am J Trop Med Hyg. 2017 Nov;97(5):1498-1502. doi: 10.4269/ajtmh.17-0094. Epub 2017 Oct 10.
9
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.
10
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
J Infect Dis. 2020 Feb 3;221(4):608-617. doi: 10.1093/infdis/jiz486.
引用本文的文献
1
New insights into the life cycle, host cell tropism, and infection amplification of spp.
Infect Immun. 2025 Jul 8;93(7):e0012325. doi: 10.1128/iai.00123-25. Epub 2025 Jun 13.
2
Navigating the Parasitic Landscape: Insights into Infection Patterns and Public Health Strategies in West Africa.
Trop Med Infect Dis. 2025 May 6;10(5):125. doi: 10.3390/tropicalmed10050125.
3
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.
Microorganisms. 2025 Mar 24;13(4):722. doi: 10.3390/microorganisms13040722.
4
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.
Curr Pharm Des. 2025;31(23):1844-1865. doi: 10.2174/0113816128338217250114073640.
5
Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.
PLoS Negl Trop Dis. 2025 Jan 3;19(1):e0012735. doi: 10.1371/journal.pntd.0012735. eCollection 2025 Jan.
6
Global Lipidomics Reveals the Lipid Composition Heterogeneity of Extracellular Vesicles from Drug-Resistant .
Metabolites. 2024 Nov 25;14(12):658. doi: 10.3390/metabo14120658.
7
Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.
Pharmaceutics. 2024 Sep 24;16(10):1239. doi: 10.3390/pharmaceutics16101239.
8
Leishmania major-induced alteration of host cellular and systemic copper homeostasis drives the fate of infection.
Commun Biol. 2024 Sep 30;7(1):1226. doi: 10.1038/s42003-024-06716-2.
9
Understanding nanoparticle-liver interactions in nanomedicine.
Expert Opin Drug Deliv. 2024 Jun;21(6):829-843. doi: 10.1080/17425247.2024.2375400. Epub 2024 Jul 4.
10
Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.
Curr Drug Discov Technol. 2025;22(2):e240524230315. doi: 10.2174/0115701638291767240513113400.
本文引用的文献
1
Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
N Engl J Med. 2010 Feb 11;362(6):504-12. doi: 10.1056/NEJMoa0903627.
2
Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Trop Med Int Health. 2009 Jan;14(1):88-92. doi: 10.1111/j.1365-3156.2008.02195.x. Epub 2008 Dec 11.
3
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.
4
Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
J Antimicrob Chemother. 2007 Oct;60(4):837-42. doi: 10.1093/jac/dkm294. Epub 2007 Aug 7.
5
Injectable paromomycin for Visceral leishmaniasis in India.
N Engl J Med. 2007 Jun 21;356(25):2571-81. doi: 10.1056/NEJMoa066536.
6
A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
Am J Trop Med Hyg. 2005 Dec;73(6):1005-11.
7
Treatment of visceral leishmaniasis.
Expert Opin Pharmacother. 2005 Dec;6(16):2821-9. doi: 10.1517/14656566.6.16.2821.
8
A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
Am J Trop Med Hyg. 2005 Nov;73(5):871-6.
9
Risk factors for kala-azar in Bangladesh.
Emerg Infect Dis. 2005 May;11(5):655-62. doi: 10.3201/eid1105.040718.
10
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Int J Antimicrob Agents. 2005 Jan;25(1):26-30. doi: 10.1016/j.ijantimicag.2004.09.011.
Zotero 插件